Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.85 USD | +2.06% | +2.48% | -27.84% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Financials (USD)
Sales 2024 * | 398M | Sales 2025 * | 443M | Capitalization | 1.49B |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -3M | EV / Sales 2024 * | 3.19 x |
Net cash position 2024 * | 220M | Net cash position 2025 * | 267M | EV / Sales 2025 * | 2.76 x |
P/E ratio 2024 * |
-82.7
x | P/E ratio 2025 * |
-476
x | Employees | 815 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Veracyte, Inc.
1 day | +2.06% | ||
1 week | +2.48% | ||
Current month | -10.42% | ||
1 month | -5.88% | ||
3 months | -24.73% | ||
6 months | -5.16% | ||
Current year | -27.84% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Stapley
CEO | Chief Executive Officer | 54 | 21-05-31 |
Rebecca Chambers
DFI | Director of Finance/CFO | 46 | 21-07-18 |
Steven French
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Evan Jones
BRD | Director/Board Member | 67 | 08-01-31 |
Robert Epstein
CHM | Chairman | 69 | 15-01-11 |
Karin Eastham
BRD | Director/Board Member | 74 | 12-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 19.85 | +2.06% | 645,022 |
24-04-19 | 19.45 | +1.30% | 1,360,124 |
24-04-18 | 19.2 | +1.80% | 813,915 |
24-04-17 | 18.86 | -0.32% | 656,372 |
24-04-16 | 18.92 | -2.32% | 682,622 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.84% | 1.49B | |
-15.64% | 11.33B | |
+39.24% | 3.16B | |
-18.79% | 2.04B | |
-34.97% | 2.14B | |
+12.52% | 975M | |
-4.37% | 731M | |
-48.78% | 364M | |
+26.64% | 371M | |
+27.51% | 245M |
- Stock Market
- Equities
- VCYT Stock